Castle Biosciences EBITDA Margin 2019-2025 | CSTL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Castle Biosciences ebitda margin from 2019 to 2025. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Castle Biosciences EBITDA Margin 2019-2025 | CSTL

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Castle Biosciences ebitda margin from 2019 to 2025. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$245.4B
Amgen (AMGN)	$157.5B
Gilead Sciences (GILD)	$146.4B
Vertex Pharmaceuticals (VRTX)	$100B
Bristol Myers Squibb (BMY)	$98.1B
CSL (CSLLY)	$85.5B
GSK (GSK)	$79.6B
Regeneron Pharmaceuticals (REGN)	$60.8B
Alnylam Pharmaceuticals (ALNY)	$59.9B
Argenex SE (ARGX)	$40.5B
BioNTech SE (BNTX)	$27.1B
Insmed (INSM)	$26.9B
Royalty Pharma (RPRX)	$20.9B
Biogen (BIIB)	$19.9B
Incyte (INCY)	$16.6B
Illumina (ILMN)	$15.5B
Genmab (GNMSF)	$15.3B
Genmab (GMAB)	$15B
Ascendis Pharma (ASND)	$11.9B
BioMarin Pharmaceutical (BMRN)	$11B
Moderna (MRNA)	$10.9B
QIAGEN (QGEN)	$10.8B
Swedish Orphan Biovitrum (BIOVF)	$10.3B
Exelixis (EXEL)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.5B
Bio-Techne Corp (TECH)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Halozyme Therapeutics (HALO)	$8.1B
Roivant Sciences (ROIV)	$8B